Patients with BRCA2 mutations tend to be more sensitive to chemotherapy and radiotherapy, leading to better prognoses in certain cancers, such as breast, ovarian, and bladder cancers [60–64]. Here, BRCA2 is linked to urinary bladder carcinoma.